Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
José Baselga, Karen A Gelmon, Shailendra Verma, et al.
The Oncologist
|
May 17, 2011
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
David Miles, Henri Roché, Miguel Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
Luca Gianni, Anna Lladó, Giulia Bianchi, et al.
Radiology
|
October 20, 2020
Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone
Michael Kosmin, Anwar R Padhani, Andrew Gogbashian, et al.
Journal of Biomedicine & Biotechnology
|
September 17, 2003
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2
Susy Scholl, Patrick Squiban, Nadine Bizouarne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
Joyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
The New England Journal of Medicine
|
October 2, 2012
Trastuzumab emtansine for HER2-positive advanced breast cancer
Sunil Verma, David Miles, Luca Gianni, et al.
British Journal of Cancer
|
November 23, 2016
Trastuzumab-associated cardiac events in the Persephone trial
Helena M Earl, Anne-Laure Vallier, Janet Dunn, et al.
The Lancet. Oncology
|
March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M Swain, David Miles, Sung-Bae Kim, et al.
Molecular Cancer Therapeutics
|
January 27, 2016
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Aysegül Ilhan-Mutlu, Matthias Osswald, Yunxiang Liao, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
José Baselga, Karen A Gelmon, Shailendra Verma, et al.
The Oncologist
|
May 17, 2011
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
David Miles, Henri Roché, Miguel Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
Luca Gianni, Anna Lladó, Giulia Bianchi, et al.
Radiology
|
October 20, 2020
Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone
Michael Kosmin, Anwar R Padhani, Andrew Gogbashian, et al.
Journal of Biomedicine & Biotechnology
|
September 17, 2003
Metastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2
Susy Scholl, Patrick Squiban, Nadine Bizouarne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results
Joyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
The New England Journal of Medicine
|
October 2, 2012
Trastuzumab emtansine for HER2-positive advanced breast cancer
Sunil Verma, David Miles, Luca Gianni, et al.
British Journal of Cancer
|
November 23, 2016
Trastuzumab-associated cardiac events in the Persephone trial
Helena M Earl, Anne-Laure Vallier, Janet Dunn, et al.
The Lancet. Oncology
|
March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
Sandra M Swain, David Miles, Sung-Bae Kim, et al.
Molecular Cancer Therapeutics
|
January 27, 2016
Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma
Aysegül Ilhan-Mutlu, Matthias Osswald, Yunxiang Liao, et al.
Page
of 6